Here is a youtube video (at below) of Dr Mor strongly endorsing Cantrixil as a significant breakthrough in the treatment of cancer. Note also his explanation of how cancer reoccurs, and the fact that new cancer treatments should look to target stem cells. All explained in good detail.
We have had this video on here before, but newer readers may be interested. Also now we know the drug is very well tolerated.....that is a very good thing.
So you have Yale endorsing the work of Novogen. Surely some investors or others, are not at a point of questioning Yale Medical School, on the basis of a OUR low share price.
Sometimes there is no explanation....the share price is just cheap and that is what all investors constantly look for. (Let say maybe I am wrong and its not so cheap afterall......I make the assumption its cheap on the basis of its $25M cap.....and because Yale and the Company say it can change the way many abdominal cancers are teated around the world....... broker say $300m PA revenues, etc)
----------------
A lot of this information came from Yale in 2015. On the 5th Feb 2016, former $10m PA Eli Lilly executive president (Bio-medicines) joined Novogen. I would suggest his decision to join this obscure, absolute minnow cancer drug development company was on the basis of that 2015 Yale research. Bryce is still with us as deputy Chairman. Check out the role of the person, who has replaced our Dr Carmine.
INDIANAPOLIS, Oct. 11, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced key appointments due to the December 31 retirements of longtime senior leaders, Bryce D. Carmine and Frank Deane, Ph.D.
Carmine, whose Lilly career spans 36 years, has led Lilly Bio-Medicines since its creation in 2009. And Deane, whose career at Lilly spans 33 years, has led global manufacturing operations since 2007. Previously, both held numerous high-level leadership posts around the globe.
John C. Lechleiter, Ph.D., chairman, president, and chief executive officer, described Carmine and Deane as "pillars of the company who have had a lasting, worldwide impact on our people and our business. We're grateful for their dedicated service."
Effective January 1:
Dave Ricks, president of Lilly USA, is being promoted to succeed Carmine as senior vice president and president of Lilly Bio-Medicines. Ricks formerly was general manager of Lilly affiliates in China and Canada. Ricks' responsibilities will include the U.S., Japan, and Europe. Bio-Medicines encompasses the therapeutic areas of neuroscience, cardiovascular, autoimmunity, musculoskeletal, and urology
"We'll certainly miss Bryce and Frank and the extraordinary leadership they provided," Lechleiter said. "At the same time, we're very fortunate to have talented leaders who are well-prepared and ready to step into these critical roles."
